Addex Therapeutics Ltd (NASDAQ:ADXN) Shares Sold by Armistice Capital LLC

Armistice Capital LLC lowered its position in Addex Therapeutics Ltd (NASDAQ:ADXN) by 92.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 43,000 shares of the company’s stock after selling 494,000 shares during the quarter. Armistice Capital LLC’s holdings in Addex Therapeutics were worth $260,000 at the end of the most recent quarter.

Addex Therapeutics Price Performance

Shares of Addex Therapeutics stock traded down $0.11 on Wednesday, hitting $8.81. The company’s stock had a trading volume of 304 shares, compared to its average volume of 16,063. Addex Therapeutics Ltd has a 52-week low of $5.00 and a 52-week high of $27.90. The firm has a fifty day moving average price of $13.46 and a 200-day moving average price of $10.16.

Addex Therapeutics (NASDAQ:ADXN) last announced its earnings results on Thursday, April 18th. The company reported ($4.06) earnings per share (EPS) for the quarter. The business had revenue of $0.21 million for the quarter. Addex Therapeutics had a negative return on equity of 277.56% and a negative net margin of 644.66%. On average, equities research analysts predict that Addex Therapeutics Ltd will post -11.8 EPS for the current fiscal year.

Addex Therapeutics Company Profile

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder.